Affimed (NASDAQ:AFMD) Stock Price Down 11.1%

Share on StockTwits

Affimed NV (NASDAQ:AFMD) shares were down 11.1% during trading on Friday . The stock traded as low as $2.53 and last traded at $2.57, approximately 2,433,867 shares changed hands during trading. An increase of 235% from the average daily volume of 726,686 shares. The stock had previously closed at $2.89.

Several research analysts have recently commented on AFMD shares. Zacks Investment Research cut shares of Affimed from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. ValuEngine raised shares of Affimed from a “sell” rating to a “hold” rating in a report on Wednesday, August 28th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $6.36.

The firm has a market capitalization of $190.91 million, a P/E ratio of -6.76 and a beta of 2.91. The business’s 50 day moving average is $2.96 and its 200-day moving average is $3.03. The company has a quick ratio of 3.47, a current ratio of 3.48 and a debt-to-equity ratio of 0.02.

Affimed (NASDAQ:AFMD) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). Affimed had a negative net margin of 30.87% and a negative return on equity of 30.94%. The firm had revenue of $4.50 million for the quarter, compared to analyst estimates of $6.46 million. Research analysts forecast that Affimed NV will post -0.08 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. State of New Jersey Common Pension Fund D acquired a new position in shares of Affimed during the second quarter valued at about $29,000. Parametric Portfolio Associates LLC acquired a new position in shares of Affimed during the second quarter valued at about $41,000. Meeder Asset Management Inc. bought a new stake in shares of Affimed during the third quarter worth about $47,000. Mackenzie Financial Corp bought a new stake in shares of Affimed during the second quarter worth about $47,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Affimed during the second quarter worth about $47,000. Hedge funds and other institutional investors own 51.01% of the company’s stock.

Affimed Company Profile (NASDAQ:AFMD)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Featured Article: Total Return

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.